Vivet Therapeutics nabs Series A funds
Paris-based Vivet Therapeutics, a developer of novel gene therapies for rare, inherited metabolic diseases, has raised 37.5 million euros in Series A financing. The investors included Novartis Venture Fund, Columbus Venture Partners, Roche Venture Fund, HealthCap, Kurma Partners and Ysios Capital.
4 May 2017•7 mins read
